2m Koreans opt out of life
Nearly two million individuals in Korea have formally declined life-extending medical interventions, choosing instead to prioritize their right to die with dignity when suffering from a terminal condition, data showed Sunday.
Data from the National Agency for Management of Life-Sustaining Treatment reveals that as of the end of August, 1,941,231 people have filed an advance health care directive to abstain from life-saving medical assistance since the system's inception in February 2018.
Women make up the majority of individuals opting for this choice, accounting for 68 percent, or 1,319,812, of those registered, with men accounting for the remaining 32 percent, or 621,419.
Less than 100,000 people registered for the health care directive in 2018. However, the number surged to 530,000 in 2019, 790,000 in 2020, 1,160,000 in 2021 and 1,570,000 in 2022.
Judging from the current monthly growth rate, the number is projected to exceed two million in October.
Five and half years have passed since the so-called "Death with Dignity Act" came into effect in Korea in February 2018. The act enabled people to refuse life-prolonging medical treatment.
Any adult over the age of 19 can register for the advance medical directive detailing treatment plans in the case of terminal illness, which they can also withdraw from at any time.
The necessary documents can be submitted to the National Agency for Management of Life-Sustaining Treatment, and the information will then be registered in a government database shared by hospitals and public health institutions. Life-sustaining treatment can be halted under several conditions if an individual falls terminally ill. The requirements include confirmation by a family member, approval from the ethics committee at a medical institution, and the agreement of the patient’s primary doctor and another doctor who is an expert in the field.
Currently, four types of treatment -- cardiopulmonary resuscitation, use of artificial respiration, hemodialysis and administration of anti-cancer drugs -- are categorized as life-extension care by the government.
(责任编辑:영화)
- Can 'Singles Inferno' boost basketball's popularity?
- 43 films to premiere at Seoul International Pride Film Festival
- S. Korea reports additional cases of lumpy skin disease in cattle
- Samsung unveils next
- Seoul shares open lower on US losses
- NewJeans, Ive win first national culture merit
- Three bidders vie for major stake in news channel YTN
- Savor the irresistible taste of tteokbokki
- [Korea Beyond Korea] Chae Man
- [Herald Interview] Ian Bostridge enjoys incorporating great works of literature into music
- STX issues new shares worth W80b to expand global business
- [속보] 한국인 163명 이스라엘서 무사히 왔다…서울공항 도착
- [KH Explains] Why foreign investors continue to be net buyers despite short selling ban
- Samyang to release tom yum flavor Buldak in US
- About half of top 500 firms remain undecided on 2024 investment plans: poll
- Artifacts with inaccurate information removed from Korean exhibition in Germany
- [Today’s K
- Japan returns favor, flies Koreans out of Israel
- S. Korea, Canada sign MOU on climate change cooperation
- Things to note to prevent disputes in international contracts: The critical clause of governing law
- 'Frasier' returns to TV but you don't need to be a superfan of the original to laugh at its jokes views+
- Seoul shares close tad higher ahead of key US jobs data views+
- YG's new girl group Babymonster to debut next month views+
- IMF maintains 2023 growth outlook for S. Korea at 1.4 pct views+
- BIFF expands award categories beyond Asian content to global titles views+
- For esports fans, more activities await beyond LoL matches views+
- [From the scene] Eye views+
- LG Electronics ups Q3 earnings guidance on upbeat demand views+
- Seoul shares open higher on US gains; Israel views+
- [Herald Review] Ive gives a sneak peek of new album, kicks off first world tour with Seoul gigs views+